2 Result(s)
within
Article
Ahmed Abbas Suleiman
Biomedicine
Biotechnology
Pharmacy
-
Article
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients
Treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used for treating non-small-cell lung cancer (NSCLC) and other cancers, is frequently associated with adverse events (AE)...
-
Article
Modeling NSCLC Progression: Recent Advances and Opportunities Available
Non-small cell lung cancer (NSCLC) is one of the leading causes of death around the world with an estimated 5-year relative survival rate of 16% at diagnosis. Development of drugs treating NSCLC is not easy, a...
